<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>RDM Clinical Laboratory Sciences</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/275F223B-424C-48A3-92FD-4372D4F309AB"><gtr:id>275F223B-424C-48A3-92FD-4372D4F309AB</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Higgins</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/97D48BFC-CE62-4229-9D74-8C468C92193E"><gtr:id>97D48BFC-CE62-4229-9D74-8C468C92193E</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:surname>Prince</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FDAD2869-F899-4428-BAE7-398507E0C029"><gtr:id>FDAD2869-F899-4428-BAE7-398507E0C029</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Callaghan</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2584032F-79DE-4183-A760-727AE45C4F32"><gtr:id>2584032F-79DE-4183-A760-727AE45C4F32</gtr:id><gtr:firstName>Yvonne</gtr:firstName><gtr:surname>Jones</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/80B1E2CF-EEB0-4EDB-B0A9-48F9F9C0EC61"><gtr:id>80B1E2CF-EEB0-4EDB-B0A9-48F9F9C0EC61</gtr:id><gtr:firstName>Bob</gtr:firstName><gtr:surname>Ford</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0400631"><gtr:id>CEFB39E2-1FDC-4230-9AB7-D33C4E7FF456</gtr:id><gtr:title>Structural analysis of the multidrug resistance P-glycoprotein</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400631</gtr:grantReference><gtr:abstractText>Drug resistance is one of the greatest medical concerns we currently face and manifests in areas such as the use of antibiotics to fight infection and the ineffectiveness of chemotherapeutic drugs in treating cancer. Resistance to drugs involves a number of defence mechanisms within cells and one of the most important is the expression of efflux pumps on their surface. Drug pumps such as P-glycoprotein (P-gp) prevent accumulation of anticancer drugs in many types of cancer cells thereby contributing to treatment failure. The ability of transporters such as P-gp to interact with a diverse array of chemically unrelated anticancer drugs remains a biochemical mystery. Despite intensive investigation over the last three decades, many questions remain. For example, what is the nature and location of the multiple drug binding sites? How is the drug binding to P-gp linked to energy production and what regions of the protein comprise the translocation pathway? Structural studies using electron microscopy have stimulated significant progress toward answering these questions; however the maximal resolution of this technique is too low to provide definitive information. A high resolution, or atomic scale, structure for P-gp would provide the missing pieces to the intriguing mechanism of multidrug transport by P-gp.</gtr:abstractText><gtr:technicalSummary>Multidrug resistance continues to prove a major obstacle in the successful treatment of cancer by chemotherapy. The resistant phenotype is produced by numerous cellular mechanisms and the actions of the plasma membrane drug efflux pump P-glycoprotein (P-gp) may be considered a first line of defence for cancer cells. Over the last decade our combined efforts have provided much important biochemical insight into the molecular mechanism of transport by P-gp and the only available structural data for the protein. From this steady progress in structural determination through 2-D electron crystallography we have reached a stage at which it is appropriate to embark on the task of elucidating high resolution information. The assembled consortium has the infrastructure and expertise for large scale P-gp production, the screening of 3-D crystal formation, 3-D crystal optimisation and solution of membrane protein structure through X-ray diffraction. The structural information will allow us to address important issues such as the location and characteristics of drug binding sites and their coupling with energy production to effect drug translocation. Crucially, a high resolution structure for P-gp will be an important resource in developing pharmacological strategies to overcome multidrug resistance in the clinic.</gtr:technicalSummary><gtr:fund><gtr:end>2008-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>236244</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Structural Genomics Consortium (SGC)</gtr:department><gtr:description>ABC protein structure determination</gtr:description><gtr:id>0CFEE63F-1021-435E-B667-E1425727E699</gtr:id><gtr:impact>Optimised protein stability assay
Mass spectroscopic analysis of membrane proteins
These assays have been developed but not yet completed or published</gtr:impact><gtr:outcomeId>SbFUdnj96ks-1</gtr:outcomeId><gtr:partnerContribution>Generation of functional assays for membrane proteins</gtr:partnerContribution><gtr:piContribution>We have joined forces with the Structural Genomics Consortium at the University of Oxford to continue oyr efforts to generate structural data on ABC transporters. The investigator leading the SGC arm is Dr Liz Carpenter.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Sutton Trust</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7EC15343-D39F-4ADB-95A2-03D5A93E4086</gtr:id><gtr:impact>We provided students in the Sutton Trust scheme information and results of our research. This was to demonstrate the nature, roles and ideals of biomedical research at the University of Oxford.

We do not have any information on follow up. Although we have been asked to come back again next year.</gtr:impact><gtr:outcomeId>810989BE7E9</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit - Cherwell School, Oxford</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E074AA2D-695A-4FCD-8729-CE0A7859B62B</gtr:id><gtr:impact>We provided a research talk on protein structures and what they provide to the research community.

We will be hosting a student in 2010 as part of the Nuffield Bursary Scheme - if successful in attaining funds.</gtr:impact><gtr:outcomeId>96A1D6EC0DF</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>168220</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Project Grant (Does inhibition of PIM kinase represent a novel mechanism to regulate the activity of ABCG2?)</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>8A6AFA37-7787-4C72-81D0-7EDB835BD6DD</gtr:id><gtr:outcomeId>2224ABA06440</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>168220</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Centre for Stem Cell Research</gtr:department><gtr:description>Project Grant</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>CBBBE207-0848-4B69-91E8-A85365B4895C</gtr:id><gtr:outcomeId>BYcLWaeB5ek0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>We developed a procedure to cryo-preserve purified and reconstituted P-glycoprotein. This was achieved primarily through an EPSRC CASE-Studentship (with University of Brighton) and CRUK funding. The MRC project grant contributed to a minor extent.</gtr:description><gtr:grantRef>G0400631</gtr:grantRef><gtr:id>2C95B577-A57C-4A5F-8E7A-3B90B0ED2E91</gtr:id><gtr:impact>We have used the discovery to submit follow-on funds to bring the technology closer to commercialisation.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>0544C742BA0</gtr:outcomeId><gtr:patentId>EP2190867</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Cryopreservation of P-glycoprotein</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have developed a number of technologies or adaptations to improve the expression, purification and storage of membrane transport proteins</gtr:description><gtr:id>A808B07B-8020-4DE6-8B9C-ADE219BB9060</gtr:id><gtr:impact>We and other members of the consortium now utilise the preparative protein methods. The cryo-preservation technique for P-glycoprotein has now been published, a patent approved and follow-on funds sought to bring this closer to commercialisation. (MRC funds played a small role in this process)</gtr:impact><gtr:outcomeId>E99285F6A53</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>membrane protein (ABC) preparation</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>64863EEC-FCF9-4348-B995-89C90BA13530</gtr:id><gtr:title>The stabilisation of purified, reconstituted P-glycoprotein by freeze drying with disaccharides.</gtr:title><gtr:parentPublicationTitle>Cryobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f24dd971b8b6f9757a2be30bd5730102"><gtr:id>f24dd971b8b6f9757a2be30bd5730102</gtr:id><gtr:otherNames>Heikal A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0011-2240</gtr:issn><gtr:outcomeId>6C5282AA8E8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E368400B-3ABD-4DCC-94B7-68CF2A453610</gtr:id><gtr:title>Generating inhibitors of P-glycoprotein: where to, now?</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/492def4213112e77ef05a61b17f74f96"><gtr:id>492def4213112e77ef05a61b17f74f96</gtr:id><gtr:otherNames>Crowley E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>2205C46879D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>259ADF8D-605F-4A18-9530-40F2A5468344</gtr:id><gtr:title>Purification and structural analyses of ABCG2.</gtr:title><gtr:parentPublicationTitle>Advanced drug delivery reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/634f0a29811f89e23b0964610a145a64"><gtr:id>634f0a29811f89e23b0964610a145a64</gtr:id><gtr:otherNames>McDevitt CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0169-409X</gtr:issn><gtr:outcomeId>c3qNKNZvnm7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>033D0F56-D708-46CA-9317-8103DFCDD13B</gtr:id><gtr:title>Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad56dd744e720c3bb05e1d22df493d95"><gtr:id>ad56dd744e720c3bb05e1d22df493d95</gtr:id><gtr:otherNames>Clark R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>31AC8F1994E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D92D3CC0-477A-423A-A8D1-8B03588531DA</gtr:id><gtr:title>Purification and 3D structural analysis of oligomeric human multidrug transporter ABCG2.</gtr:title><gtr:parentPublicationTitle>Structure (London, England : 1993)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/634f0a29811f89e23b0964610a145a64"><gtr:id>634f0a29811f89e23b0964610a145a64</gtr:id><gtr:otherNames>McDevitt CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0969-2126</gtr:issn><gtr:outcomeId>24932F1B114</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9A154E7-82CC-4D07-97BB-AF2B7AE410F9</gtr:id><gtr:title>Structural insights into P-glycoprotein (ABCB1) by small angle X-ray scattering and electron crystallography.</gtr:title><gtr:parentPublicationTitle>FEBS letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/634f0a29811f89e23b0964610a145a64"><gtr:id>634f0a29811f89e23b0964610a145a64</gtr:id><gtr:otherNames>McDevitt CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0014-5793</gtr:issn><gtr:outcomeId>79CBC2B4523</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B1F88BC-65B8-4E4F-B067-0FD8E73B4C53</gtr:id><gtr:title>Is ATP binding responsible for initiating drug translocation by the multidrug transporter ABCG2?</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/634f0a29811f89e23b0964610a145a64"><gtr:id>634f0a29811f89e23b0964610a145a64</gtr:id><gtr:otherNames>McDevitt CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn><gtr:outcomeId>A486CC1B3DB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6F62760-1E4C-4CF7-946A-B61D1CEA4BB5</gtr:id><gtr:title>P-glycoprotein: so many ways to turn it on.</gtr:title><gtr:parentPublicationTitle>Journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe9cbccf8235fad6cd112f0dd4c1c80b"><gtr:id>fe9cbccf8235fad6cd112f0dd4c1c80b</gtr:id><gtr:otherNames>Callaghan R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0091-2700</gtr:issn><gtr:outcomeId>D9AA7261012</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76D1263B-9515-448E-8051-C7E44D9A8DB9</gtr:id><gtr:title>How can we best use structural information on P-glycoprotein to design inhibitors?</gtr:title><gtr:parentPublicationTitle>Pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/634f0a29811f89e23b0964610a145a64"><gtr:id>634f0a29811f89e23b0964610a145a64</gtr:id><gtr:otherNames>McDevitt CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0163-7258</gtr:issn><gtr:outcomeId>9582FB93CAD</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400631</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>